Skip to main navigation
Clene Inc. Clene Inc.
  • About Us
    • Leadership
    • Board of Directors
  • Science
    • About CNM-Au8®
  • Pipeline
  • Patients
    • EAP
  • Investors
    • Overview
    • News & Events
      • Press Releases
      • News
      • Events
    • Presentations
      • Investor Presentation
      • Scientific Posters & Presentations
      • Webinars
      • Publications
    • Corporate Governance
      • Executive Management
      • Board of Directors
      • Committee Composition
      • Governance Documents
    • Financial Information
      • SEC Filings
      • Annual Reports
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Analyst Coverage
    • Investor Resources
      • Investor FAQs
      • Information Request Form
      • Investor Email Alerts
  • Contact
Clene Inc. Clene Inc.
  • About Us
    • Leadership
    • Board of Directors
  • Science
    • About CNM-Au8®
  • Pipeline
  • Patients
    • EAP
  • Investors
    • Overview
    • News & Events
      • Press Releases
      • News
      • Events
    • Presentations
      • Investor Presentation
      • Scientific Posters & Presentations
      • Webinars
      • Publications
    • Corporate Governance
      • Executive Management
      • Board of Directors
      • Committee Composition
      • Governance Documents
    • Financial Information
      • SEC Filings
      • Annual Reports
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Analyst Coverage
    • Investor Resources
      • Investor FAQs
      • Information Request Form
      • Investor Email Alerts
  • Contact

News

CNM-Au8 Lessens Vision Problems in RRMS Patients in Phase 2 Trial
August 17, 2022
Clene to Move Forward in MS Despite COVID-19-Halted Phase II Trial
August 16, 2022
CNM-Au8 Displays Positive Topline Results in Multiple Sclerosis, Supportive of Phase 3 Trial
August 16, 2022
CNM-Au8 Reduces Mortality in ALS, Prenatal Exposure to ASMs Increases Neurodevelopmental Disorders, FDA Grants Tentative Approval to FT218
July 23, 2022
EU Committee Urges Orphan Drug Status for Clene’s CNM-Au8 for ALS
July 22, 2022
CNM-Au8 Shows Continued Decreases in ALS Mortality, Updated Open-Label Findings Show
July 21, 2022
Early CNM-Au8 Treatment Leads to Significant Survival Benefit in Study
July 18, 2022
Decreased Mortality in Amyotrophic Lateral Sclerosis Seen in Open-Label Extension Study of Nanocrystalline Gold
July 18, 2022
Burr bill, Novartis makeover, ALS update: a BioCentury podcast
July 18, 2022
Clene’s CNM-Au8 boosts survival in amyotrophic lateral sclerosis trial
July 15, 2022

Pagination

  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Current page 2
  • Page 3
  • Page 4
  • Next page next ›
  • Last page last »


1-801-676-9695
info@CleneNanomedicine.com
@CleneNano

Headquarters and Development

6550 South Millrock Drive, Suite G50
Salt Lake City, Utah 84121

Manufacturing, R&D

500 Principio Parkway West Suite 400
North East, Maryland 21901

Clene Nanomedicine, Inc. is a wholly owned subsidiary of Clene Inc. | © 2023 Clene Nanomedicine, Inc. - All rights reserved